# A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients

> **NCT00384202** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 112 (actual)

## Conditions studied

- Transplantation

## Interventions

- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00384202
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2014-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384202, "A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00384202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*